INS and type 1 diabetes mellitus: A new series of experiments was carried on the evolution of bone modelling factors in the appearance of Charcot neuroarthropathy with the implication of the receptor activator of nuclear factor-B ligand (RANKL) and its natural antagonist, osteoprotegerin (OPG) [12,13], it has already been described the value of OPG can vary after insulin treatment in patients living with type 1 diabetes [14], this may refine the hypotheses and the results of our study, however, the RANKL value was not evaluated in that study [14].